Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature

References

• Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MCB, Su J, Xu F, Weinstock H. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–193. doi:10.1097/OLQ.0b013e318286bb53.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–664. doi:10.1097/OLQ.0000000000000193.
   PubMed Web of Science ®Google Scholar
• De Villiers E-M, Fauquet C, Broker TR, Bernard H-U, Zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17–27. doi:10.1016/j.virol.2004.03.033.
   PubMed Web of Science ®Google Scholar
• Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res. 2012;5(1):18–23. doi:10.1158/1940-6207.CAPR-11-0542.
   PubMed Web of Science ®Google Scholar
• Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Women’s Health. 2012;21(10):1031–1037. doi:10.1089/jwh.2011.3385.
   PubMed Web of Science ®Google Scholar
• Simard EP, Naishadham D, Saslow D, Jemal A. Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975-2009. Gynecol Oncol. 2012;127(3):611–615. doi:10.1016/j.ygyno.2012.08.021.
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, Stubbs RW, Bertozzi-Villa A, Morozoff C, Charara R, Allen C, Naghavi M, Murray CJL. Trends and patterns of disparities in cancer mortality among us counties, 1980-2014. JAMA. 2017;317(4):388–406. doi:10.1001/jama.2016.20324.
   PubMed Web of Science ®Google Scholar
• Yoo W, Kim S, Huh WK, Dilley S, Coughlin SS, Partridge EE, Chung Y, Dicks V, Lee J-K, Bae S, et al. Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS ONE. 2017;12(2):e0172548. doi:10.1371/journal.pone.0172548.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–278. doi:10.1016/S1470-2045(05)70101-7.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. The Lancet. 2006;367(9518):1247–1255. doi:10.1016/S0140-6736(06)68439-0.
   PubMed Web of Science ®Google Scholar
• Lin X, Rodgers L, Zhu L, Stokley S, Meites E, Markowitz LE. Human papillomavirus vaccination coverage using two-dose or three-dose schedule criteria. Vaccine. 2017;35(43):5759–5761. doi:10.1016/j.vaccine.2017.08.090.
   PubMed Web of Science ®Google Scholar
• Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, Williams CL, Meyer SA, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents Aged 13–17 Years — united States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(33):874–882. doi:10.15585/mmwr.mm6633a2.
   PubMed Web of Science ®Google Scholar
• Healthy People 2020. Immunization and infectious diseases, 2015. 2015; https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives.
   Google Scholar
• Hirth JM, Rahman M, Smith JS, Berenson AB. Regional variations in HPV vaccination among 9–17 year old adolescent females from the BRFSS, 2008–2010. Hum Vaccin Immunother. 2014;10(12):3475–3483. doi:10.4161/21645515.2014.980202.
   PubMed Web of Science ®Google Scholar
• Rahman M, McGrath CJ, Berenson AB. Geographic variation in human papillomavirus vaccination uptake among 13–17 year old adolescent girls in the United States. Vaccine. 2014;32(21):2394–2398. doi:10.1016/j.vaccine.2014.02.097.
   PubMed Web of Science ®Google Scholar
• Jeudin P, Liveright E, Del Carmen MG, Perkins RB. Race, ethnicity and income as factors for HPV vaccine acceptance and use. Hum Vaccin Immunother. 2013;9(7):1413–1420. doi:10.4161/hv.24422.
   PubMed Web of Science ®Google Scholar
• Agénor M, Pérez AE, Peitzmeier SM, Borrero S. Racial/ethnic disparities in human papillomavirus vaccination initiation and completion among U.S. women in the post-Affordable Care Act era. Ethn Health. 2018:1–15. doi:10.1080/13557858.2018.1427703.
   PubMedGoogle Scholar
• Zhan FB, Lin Y. Racial/ethnic, socioeconomic, and geographic disparities of cervical cancer advanced-stage diagnosis in Texas. Women’s Health Issues. 2014;24(5):519–527. doi:10.1016/j.whi.2014.06.009.
   PubMed Web of Science ®Google Scholar
• Niccolai LM, Julian PJ, Bilinski A, Mehta NR, Meek JI, Zelterman D, Hadler JL, Sosa L. Geographic poverty and racial/ethnic disparities in cervical cancer precursor rates in Connecticut, 2008–2009. Am J Public Health. 2013;103(1):156–163. doi:10.2105/AJPH.2011.300447.
   PubMed Web of Science ®Google Scholar
• D’Souza G, Westra WH, Wang SJ, Van Zante A, Wentz A, Kluz N, Rettig E, Ryan WR, Ha PK, Kang H, et al. Differences in the prevalence of human papillomavirus (hpv) in head and neck squamous cell cancers by sex, race, anatomic tumor site, and hpv detection method. JAMA Oncol. 2017;3(2):169–177. doi:10.1001/jamaoncol.2016.3067.
   PubMed Web of Science ®Google Scholar
• Auluck A, Walker BB, Hislop G, Lear SA, Schuurman N, Rosin M. Socio-economic deprivation: a significant determinant affecting stage of oral cancer diagnosis and survival. BMC Cancer. 2016;16:569. doi:10.1186/s12885-016-2579-4.
   PubMed Web of Science ®Google Scholar
• Berenson AB, Laz TH, Rahman M. Reduction in vaccine-type human papillomavirus prevalence among women in the United States, 2009–2012. J Infect Dis. 2016;214(12):1961–1964. doi:10.1093/infdis/jiw515.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–393. doi:10.1093/infdis/jit192.
   PubMed Web of Science ®Google Scholar
• Oliver SE, Unger ER, Lewis R, McDaniel D, Gargano JW, Steinau M, Markowitz LE. Prevalence of human papillomavirus among females after vaccine introduction—national Health and Nutrition Examination Survey, United States, 2003–2014. J Infect Dis. 2017;216(5):594–603. doi:10.1093/infdis/jix244.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. GLOBOCAN 2012 cancer incidence and mortality worldwide. Lyon (France): International Agency for Research on Cancer; 2016.
   Google Scholar
• American Cancer Society. Key Statistics for Cervical Cancer. 2018; https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html. Accessed January 8, 2018.
   Google Scholar
• American Cancer Society. Cancer facts & figures 2017. Atlanta, GA: Guttmacher Institute; 2017.
   Google Scholar
• Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American younth, 2000. Perspect Sex Reprod Health. 2004;36(1):11–19. doi:10.1363/psrh.36.11.04.
   PubMed Web of Science ®Google Scholar
• Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198(5):500.e501–500.e507. doi:10.1016/j.ajog.2008.03.064.
   Web of Science ®Google Scholar
• Omland T, Lie KA, Akre H, Sandlie LE, Jebsen P, Sandvik L, Nymoen DA, Bzhalava D, Dillner J, Brøndbo K, et al. Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia. PLoS ONE. 2014;9(6):e99114. doi:10.1371/journal.pone.0099114.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol. 2012;6(Suppl 1):16–24. doi:10.1007/s12105-011-0304-9.
   PubMedGoogle Scholar
• Simard P, Ward M, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62(2):118–128. doi:10.3322/caac.20141.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Chaturvedi AK. HPV-associated oropharyngeal cancers—are they preventable? Cancer Prev Res. 2011;4(9):1346–1349. doi:10.1158/1940-6207.CAPR-11-0379.
   PubMed Web of Science ®Google Scholar
• Hirth JM, Chang M, Resto VA. Prevalence of oral human papillomavirus by vaccination status among young adults (18–30years old). Vaccine. 2017;35(27):3446–3451. doi:10.1016/j.vaccine.2017.05.025.
   PubMed Web of Science ®Google Scholar
• Kreimer AR. Prospects for prevention of HPV-driven oropharynx cancer. Oral Oncol. 2014;50(6):555–559. doi:10.1016/j.oraloncology.2013.06.007.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter DL, Kitchener HC, Castellsague X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet. 2007;369(9580):2161–2170. doi:10.1016/S0140-6736(07)60946-5.
   PubMed Web of Science ®Google Scholar
• Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci. 2016;113(18):5107–5112. doi:10.1073/pnas.1515528113.
   PubMed Web of Science ®Google Scholar
• Dorell C, Stokley S, Yankey D, Cohn A, Markowitz LE. National, state, and local area vaccination coverage among adolescents aged 13–17 Years — united States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(32):1018–1023.
   PubMedGoogle Scholar
• Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002;186(10):1396–1402. doi:10.1086/344354.
   PubMed Web of Science ®Google Scholar
• Hariri S, Dunne EF, Sternberg M, Unger ER, Meadows KS, Karem KL, Markowitz LE. Seroepidemiology of human papillomavirus type 11 in the United States: results from the Third National Health and Nutrition Examination Survey, 1991–1994. Sex Transm Dis. 2008;35(3):298–303. doi:10.1097/OLQ.0b013e31815abaef.
   PubMed Web of Science ®Google Scholar
• Revzina NV, DiClemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS. 2005;16(8):528–537. doi:10.1258/0956462054679214.
   PubMed Web of Science ®Google Scholar
• Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813. doi:10.1001/jama.297.8.813.
   PubMed Web of Science ®Google Scholar
• Dunne EF, Sternberg M, Markowitz LE, McQuillan G, Swan D, Patel S, Unger ER. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States—national Health and Nutrition Examination Survey, 2003–2006: opportunity to measure HPV vaccine impact? J Infect Dis. 2011;204(4):562–565. doi:10.1093/infdis/jir342.
   PubMed Web of Science ®Google Scholar
• Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006;194(8):1044–1057. doi:10.1086/507432.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee J-H, Papenfuss MR, Abrahamsen M, Jolles E, Nielson CM, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2036–2043. doi:10.1158/1055-9965.EPI-08-0151.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968. doi:10.1542/peds.2015-1968.
   PubMed Web of Science ®Google Scholar
• Guo F, Hirth JM, Berenson AB. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years). Hum Vaccin Immunother. 2015;11(10):2337–2344. doi:10.1080/21645515.2015.1066948.
   PubMed Web of Science ®Google Scholar
• Liu G, Unger ER, Hariri S, Steinau M, Markowitz LE. Prevalence of 9-valent human papillomavirus types by race/ethnicity in the Prevaccine Era, United States, 2003–2006. Sex Transm Dis. 2016;43(10):633–636. doi:10.1097/OLQ.0000000000000492.
   PubMed Web of Science ®Google Scholar
• Lewis RM, Markowitz LE, Gargano JW, Steinau M, Unger ER. Prevalence of genital human papillomavirus among sexually experienced males and females aged 14–59 Years, United States, 2013–2014. J Infect Dis. 2018;217(6):869–877. doi:10.1093/infdis/jix655.
   PubMed Web of Science ®Google Scholar
• Gargano JW, Unger ER, Liu G, Steinau M, Meites E, Dunne E, Markowitz LE. Prevalence of genital human papillomavirus in Males, United States, 2013–2014. J Infect Dis. 2017;215(7):1070–1079. doi:10.1093/infdis/jix057.
   PubMed Web of Science ®Google Scholar
• Bansal M, Zhao C. Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep papanicolaou cytology. J Low Genit Tract Dis. 2011;15(2):105–109. doi:10.1097/LGT.0b013e3181f41ee4.
   PubMed Web of Science ®Google Scholar
• Manhart LE, Holmes KK, Koutsky LA, Wood TR, Kenney DL, Feng Q, Kiviat NB. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis. 2006;33(8):502–508. doi:10.1097/01.olq.0000204545.89516.0a.
   PubMed Web of Science ®Google Scholar
• Banister CE, Messersmith AR, Cai B, Spiryda LB, Glover SH, Pirisi L, Creek KE. disparity in the persistence of high-risk human papillomavirus genotypes between African American and European American women of college age. J Infect Dis. 2015;211(1):100–108. doi:10.1093/infdis/jiu394.
   PubMed Web of Science ®Google Scholar
• Niccolai LM, Russ C, Julian PJ, Hariri S, Sinard J, Meek JI, McBride V, Markowitz LE, Unger ER, Hadler JL, et al. Individual and geographic disparities in human papillomavirus types 16/18 in high‐grade cervical lesions. Cancer. 2013;119(16):3052–3058. doi:10.1002/cncr.28038.
   PubMed Web of Science ®Google Scholar
• Vidal AC, Smith JS, Valea F, Bentley R, Gradison M, Yarnall KSH, Ford A, Overcash F, Grant K, Murphy SK, et al. HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. Cancer Causes Control. 2014;25(8):1055–1062. doi:10.1007/s10552-014-0406-2.
   PubMed Web of Science ®Google Scholar
• Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Steinau M, Markowitz LE, et al. Human papillomavirus genotypes in high grade cervical lesions in the United States. J Infect Dis. 2012;206: 1878–1886.
   Web of Science ®Google Scholar
• Hopenhayn C, Christian A, Christian WJ, Watson M, Unger ER, Lynch CF, Peters ES, Wilkinson EJ, Huang Y, Copeland G, et al. Prevalence of human papillomavirus types in invasive cervical cancers from seven US cancer registries prior to vaccine introduction. J Low Genit Tract Dis. 2014;18(2):182–189. doi:10.1097/LGT.0b013e3182a577c7.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, Bernstein DI. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130(2):e249–e256. doi:10.1542/peds.2011-3587.
   PubMed Web of Science ®Google Scholar
• Berenson AB, Hirth JM, Chang M. Change in human papillomavirus prevalence among U.S. Women aged 18–59 years, 2009–2014. Obstetrics Gynecol. 2017;130(4):693–701. doi:10.1097/AOG.0000000000002193.
   PubMed Web of Science ®Google Scholar
• Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, Ahmed S, Palmer T, Pollock KGJ. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis. 2016;22(1):56–64. doi:10.3201/eid2201.150736.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Liu B, Bateson D, McNamee K, Garefalakis M, Phillips S, Cummins E, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14(10):958–966. doi:10.1016/S1473-3099(14)70841-2.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus–related and –unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612–619. doi:10.1200/JCO.2007.14.1713.
   PubMed Web of Science ®Google Scholar
• Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, Reichman ME, Wu X, Chaturvedi AK, Kawaoka K. Burden of potentially human papillomavirus‐associated cancers of the oropharynx and oral cavity in the US, 1998–2003. Cancer. 2008;113(10):2901–2909. doi:10.1002/cncr.23745.
   PubMed Web of Science ®Google Scholar
• Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, Pan Y, Lazcano-Ponce E, Salmeron J, Giuliano AR. Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trial. J Infect Dis. 2016;214(8):1276–1283. doi:10.1093/infdis/jiw359.
   PubMed Web of Science ®Google Scholar
• Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE. 2013;8(7):e68329. doi:10.1371/journal.pone.0068329.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong Z-Y, Xiao W, Kahle L, Gillison ML. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36(3):262–267. doi:10.1200/JCO.2017.75.0141.
   PubMed Web of Science ®Google Scholar
• Cheruvu VK, Bhatta MP, Drinkard LN. Factors associated with parental reasons for “no-intent” to vaccinate female adolescents with human papillomavirus vaccine: national Immunization Survey - Teen 2008–2012. BMC Pediatr. 2017;17:52. doi:10.1186/s12887-017-0969-7.
   PubMed Web of Science ®Google Scholar
• Rosen BL, Shepard A, Kahn JA, Health Care US. Clinicians’ knowledge, attitudes, and practices regarding human papillomavirus vaccination: a qualitative systematic review. Acad Pediatr. 2018;18(2, Supplement):S53–S65. doi:10.1016/j.acap.2017.10.007.
   PubMed Web of Science ®Google Scholar
• Daley EM, Vamos CA, Thompson EL, Zimet GD, Rosberger Z, Merrell L, Kline NS. The feminization of HPV: how science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. Papillomavirus Res. 2017;3:142–148. doi:10.1016/j.pvr.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Ratanasiripong NT. Human papillomavirus vaccine increases high-risk sexual behaviors: a myth or valid concern. J Sch Nurs. 2014;30(6):456–463. doi:10.1177/1059840513520042.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Lin M, Wallington SF, Hanchate AD. Impact of school-entry and education mandates by states on HPV vaccination coverage: analysis of the 2009–2013 National Immunization Survey-Teen. Hum Vaccin Immunother. 2016;12(6):1615–1622. doi:10.1080/21645515.2016.1150394.
   PubMed Web of Science ®Google Scholar
• Conroy K, Rosenthal SL, Zimet GD, Jin Y, Bernstein DI, Glynn S, Kahn JA. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Women’s Health. 2009;18(10):1679–1686. doi:10.1089/jwh.2008.1329.
   PubMed Web of Science ®Google Scholar
• Keating KM, Brewer NT, Gottlieb SL, Liddon N, Ludema C, Smith JS. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health. 2008;43(4):S61–S67. doi:10.1016/j.jadohealth.2008.06.015.
   PubMed Web of Science ®Google Scholar
• Berenson AB. An update on barriers to adolescent human papillomavirus vaccination in the USA. Expert Rev Vaccines. 2015;14(10):1377–1384. doi:10.1586/14760584.2015.1078240.
   PubMed Web of Science ®Google Scholar
• Dempsey A, Cohn L, Dalton V, Ruffin M. Worsening disparities in HPV vaccine utilization among 19–26 year old women. Vaccine. 2011;29(3):528–534. doi:10.1016/j.vaccine.2010.10.051.
   PubMed Web of Science ®Google Scholar
• Cook RL, Zhang J, Mullins J, Kauf T, Brumback B, Steingraber H, Mallison C. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health. 2010;47(6):596–599. doi:10.1016/j.jadohealth.2010.09.015.
   PubMed Web of Science ®Google Scholar
• Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Curtis CR, MacNeil J, Markowitz LE, Singleton JA. National and state vaccination coverage among adolescents aged 13 through 17 years — united States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):850–858. doi:10.15585/mmwr.mm6533a4.
   PubMed Web of Science ®Google Scholar
• Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR, MacNeil J, Markowitz LE, Stokley S. National and state vaccination coverage among adolescents aged 13 through 17 years — united States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(29):784–792.
   PubMed Web of Science ®Google Scholar
• Elam-Evans LD, Yankey D, Jeyarajah J, Singleton JA, Curtis RC, MacNeil J, Hariri S. National and state vaccination coverage among adolescents aged 13 through 17 years — united States, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(29):625–633.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years — united States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(34):685–693.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years — united States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(34):671–677.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years — united States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(33):1117–1123.
   PubMedGoogle Scholar
• Choi Y, Eworuke E, Segal R. What explains the different rates of human papillomavirus vaccination among adolescent males and females in the United States? Papillomavirus Res. 2016;2:46–51. doi:10.1016/j.pvr.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Nelson EJ, Hughes J, Oakes JM, Pankow JS, Kulasingam SL. Geospatial patterns of human papillomavirus vaccine uptake in Minnesota. BMJ Open. 2015;5(8):e008617. doi:10.1136/bmjopen-2015-008617.
   PubMed Web of Science ®Google Scholar
• Eberth JM, Zhang X, Hossain M, Tiro JA, Holt JB, Vernon SW. County-level estimates of human papillomavirus vaccine coverage among young adult women in Texas, 2008. Texas Public Health J. 2013;65(1):37–40.
   PubMedGoogle Scholar
• Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson HW, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007;56(RR02):1–24.
   PubMedGoogle Scholar
• Advisory Committee on Immunization Practices. Recommendations on the use of quadrivalent human papillomavirus vaccine in males — advisory committee on immunization practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705–1708.
   PubMedGoogle Scholar
• Advisory Committee on Immunization Practices. FDA Licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630–632.
   PubMedGoogle Scholar
• Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10(12):845–852. doi:10.1016/S1473-3099(10)70219-X.
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300–304.
   PubMed Web of Science ®Google Scholar
• Dobson SM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of hpv vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA. 2013;309(17):1793–1802. doi:10.1001/jama.2013.1625.
   PubMed Web of Science ®Google Scholar
• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination — updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65(49):1405–1408. doi:10.15585/mmwr.mm6549a5.
   PubMed Web of Science ®Google Scholar
• William WW, Lu P-J, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, et al. Surveillance of vaccination coverage among adult populations — united States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(11):1–28. doi:10.15585/mmwr.mm6601a1.
   PubMedGoogle Scholar
• Moss JL, Reiter PL, Brewer NT. Correlates of human papillomavirus (HPV) vaccine coverage: A state-level analysis. Sex Transm Dis. 2015;42(2):71–75. doi:10.1097/OLQ.0000000000000225.
   PubMed Web of Science ®Google Scholar